Micreos is a platform biotech company dedicated to the discovery and development of recombinant proteins for chronic Dermatology and Oncology conditions.
Our engineered endolysin technology quickly kills harmful pathogens while preserving the health enhancing microbiome. Endolysins are associated with a low risk of drug resistance development, are highly effective against biofilms and are effective across a broad pH range which is critical important in dermatology. This unlocks a revolutionary approach to treating a wide range of diseases, especially chronic conditions.
Micreos is specialised in dermatology and derm-oncology with our 2 lead development candidates focused on eliminating Staphylococcus aureus (S. aureus) colonisation in patients living with Atopic Dermatitis (AD) and Cutaneous T-cell lymphoma (CTCL).
S. aureus is a common bacteria that is known to cause significant patient morbidity and mortality globally. S. aureus is found on around 20-30% of healthy people, but in chronic conditions like CTCL and Atopic Dermatitis, the rate is as high as 80%. S. aureus worsens clinical outcomes through the release of toxins and super-antigens leading to the proliferation of malignant T-cells in CTCL and more frequent and more severe flare in Atopic Dermatitis.
30+ years of Pharma, Med-Tech & Diagnostic experience spanning the entire value-chain from drug discovery & development to manufacturing to commercial leadership in large, global healthcare organizations.
View on LinkedIn
10+ years of big pharma, diagnostic & biotech finance experience across the value chain in global, regional and local affiliate roles in Switzerland, US, Czech Republic and Germany.
View on LinkedIn
Internationally recognized expert with 14+ years of experience in endolysin research, genetic engineering, and the development of protein-based antimicrobials and diagnostics.
View on LinkedIn
30+ years of diverse experience in drug development, pharmaceutical value, access & pricing, as well as a renowned expert on health economic outcomes research.
View on LinkedIn
Our vision is to fully harness the potential of our engineered endolysin to revolutionise the treatment of Dermatology, Oncology and Blood related medical conditions that are bacterial induced. We have an industry-leading discovery and development pipeline, including:
- Engineered endolysins in development for in-house use in Atopic Dermatitis (AD) and Cutaneous T-cell Lymphoma (CTCL) - A world-class team and state-of-the-art laboratory, ready for partnering on new bacterial targets and diseases
We welcome collaboration with partners who share our ambition, please contact CEO Matt Regan:
Get in touch